Imaging solid tumors using fluoride-labeled boronophenylalanine PET
Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors
This study is testing a new imaging method to see if a special tracer can help identify solid tumors in patients who might benefit from a targeted cancer treatment called boron neutron capture therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05538676 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the biological activity of solid tumors through positron emission tomography (PET) using fluoride-labeled boronophenylalanine (F-BPA) as a tracer. The study aims to enhance the understanding of boron neutron capture therapy (BNCT), a targeted radiotherapy that selectively kills tumor cells while preserving normal tissue. By utilizing PET imaging, researchers can obtain quantitative data on the distribution of BPA in tumors, which helps identify patients who may benefit from BNCT treatment. The methodology focuses on accurately assessing tumor size and BPA concentration ratios in surrounding tissues to optimize patient recruitment for future clinical trials.
Who should consider this trial
Good fit: Ideal candidates include adults with clinically diagnosed solid tumors such as recurrent head and neck cancer, glioma, pancreatic cancer, and osteosarcoma.
Not a fit: Patients who are pregnant, have renal failure, or suffer from claustrophobia may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and targeted treatments for patients with solid tumors.
How similar studies have performed: While BNCT is an advanced therapy, the use of PET imaging with BPA is a novel approach that has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with clinically diagnosed solid tumors, including but not limited to recurrent head and neck cancer, glioma, pancreatic cancer, osteosarcoma, etc.; The selected subjects need to sign the informed consent. Exclusion Criteria: * Pregnant women; renal failure (serum Cr\>3mg/dl); Patients with claustrophobia;
Where this trial is running
Wuhan, Hubei
- TongjiHospital — Wuhan, Hubei, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.